维普期刊资源整合服务平台（V6.5）

94篇 您的检索式：作者名="Chamuleau"

选中清除导出查看参考文献查看引证文献引用追踪共5页首页上一页第1页下一页末页 /5 跳转

	题名	作者	年代	出处	被引量
1	Future of bioartifi cial liver support显示文摘Many different artificial liver support systems(biological and non-biological) have been developed,tested pre-clinically and some have been applied in clinical trials.Based on theoretical considerations a biological artificial liver(BAL) should be preferred above the non-biological ones.However,clinical application of the BAL is still experimental.Here we try to analyze which hurdles have to be taken before the BAL will become standard equipment in the intensive care unit for patients with acute liver failure or acute deterioration of chronic liver disease.	Robert AFM Chamuleau	2009	World Journal of Gastrointestinal Surgery2009，1，1：	7
2	为在尖锐的肝失败病人预言差的结果合并动力学显示文摘 Acute liver failure (ALF), also known as fulminant hepatic failure (FHF), is a devastating clinical syndrome with a high mortality of 60%-90%. An early and exact assessment of the severity of ALF together with prediction of its further development is critical in order to determine the further management of the patient. A number of prognostic models have been used for outcome prediction in ALF patients but they are mostly based on the variables measured at one time point, mostly at admission. ALF patients rarely show a static state: rapid progress to a life threatening situation occurs in many patients. Since ALF is a dynamic process, admission values of prognostic variables change over time during the clinical course of the patient. Kumar et al developed a prognostic model [ALF early dynamic (ALFED)] based on early changes in values of variables which predicted outcome. ALFED is a model which seems to be worthwhile to test in ALF patients in other parts of the world with different aetiologies. Since the exact pathophysiology of ALF is not fully known and is certainly complex, we believe that adding promising variables involved in the pathophysiology of ALF to the dynamic approach might even further improve prognostic performance. We agree with Kumar et al that an improved dynamic prognostic model should be based on simplicity (easily to be performed at the bedside) and accuracy. Our comments presented in this paper may be considered as recommendations for future optimization of ALF prediction models.	Robert AFM Chamuleau Kama A Wlodzimirow Ameen Abu-Hanna	2012	World Journal of Gastrointestinal Surgery2012，4，12：	2
3	A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality显示文摘	Kama A. Wlodzimirow Saeid Eslami Ameen Abu‐Hanna Martin Nieuwoudt Robert A. F. M. Chamuleau	2012	Liver Int2012，，1：	2
4	Outcome of regional and local ablative therapies for hepatocellular carcinoma:a collective review显示文摘	JASEN M C VAN HILLEGERSBERG R CHAMULEAU R A	2005	Eur J Surg Oncol2005，31，4：	1
5	Papillary muscle rupture following percutaneous mitral valvuloplasty显示文摘	Onsea K Chamuleau S Stella P		0，，3：	1
6	Future of bioartificial liver support显示文摘	CHAMULEAU R A	2009	World J Gastrointest Surg2009，1，1：	1
7	Targeting cell death in the reperfused heart: pharmaco-logical approaches for cardioprotection显示文摘	Oerlemans MI Koudstaal S Chamuleau SA		Int J0，，：	1
8	Activated partialthromboplati time (aPTT) monitoring to achieve therapeutic anticoagulation befor and after introducing a nomogram for adjunctive hepar in treatmeen with thromobolytic therapy for acute myocardial infarction显示文摘	Chamuleau Robbert J de Winter	1998	Inter Journal of Cardiology1998，6724，：	1
9	MHC class Ⅱ molecules in tumour immunology: prognostic marker and target for immune modulation 显示文摘	Chamuleau ME Ossenkoppele GJ van de Loosdrecht AA	2006	Immunobiology2006，211，68：	1
10	ApoAⅤ reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis显示文摘	Schaap FG Rensen PC Voshol PJ Vrins C Van der Vliet HN Chamuleau RA	2004	J Biol Chem2004，279，27：	1
11	Clinical application of bioartificial liver support systems显示文摘	van de Kerkhove MP Hoekstra R Chamuleau RA		0，，02：	1
12	Usefulness of fractional flow reserve for risk stratification of patients with multivessel coronary artery disease and an intermediate stenosis显示文摘	Chamuleau SAJ Meuwissen M Koch KT	2002	Am J Cardiol2002，89，4：	1
13	Hyperemic Stenosis Resistance Index for Evaluation of Functional Coronary Lesion Severity显示文摘	Martijn Meuwissen Maria Siebes Steven A.J. Chamuleau Berthe L.F. van Eck-Smit Karel T. Koch Robbert J. de Winter Jan G.P. Tijssen Jos A.E. Spaan Jan J. Piek	2002	Circulation: Journal of the American Heart Association2002，，：	1
14	Class Ⅱ Associated Invariant Chain Peptide Expression Repre sents a Novel Parameter for Flow Cytometric Detection of A cute Promyelocytic Leukemia显示文摘	van Luijn M M Westers T M Chamuleau M E D	2011	The American Journal of Pathology2011，179，5：	1
15	Targeting cell death in the reperfused heart: pharmacological approaches for cardioprotectian显示文摘	Oerlemans M I Koudstaal S Chamuleau S A	2013	Int J Cardiol2013，165，：	1
16	Which are the right cells to be used in a bioartificial liver显示文摘	Chamuleau RA Deurholt T Hoekstra R		0，，04：	1
17	Clinieal application of bioartificial liver support systems显示文摘	Hoekstrak Chamuleau RA	2004	Ann Surg2004，240，2：	1
18	Which are the right cells to be used in a bioartificial liver显示文摘	CHAMULEAU RA DEURHOLT T HOEKSTRA R	2005	Metab Brain Dis2005，20，4：	1
19	Revers-ibility of cholestatic changes following experimentalcommon bile duct obstruction: fact of fantasy显示文摘	Aronson DG Chamuleau RA Frederiks WM	1993	Hepatol1993，18，1：	1
20	Usefulness of fractional flow reserve for risk stratification of patients with multivessel coronary artery disease and an intermediate stenosis显示文摘	CHAMULEAU S A MEUWISSEN M KOCH KT	2002	Am J Cardiol2002，89，：	1

返回顶部每页显示：

共5页首页上一页第1页下一页末页 /5 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示